ࡱ; gd  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcfhRoot Entry  \pCalc Ba=B  !=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_) #,##0\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_)'""($"#,##0.00_);[RED]"($"#,##0.00\) #,##0.00                + ) , *   (  (  $       (8  $  $  $   ( ( `> advaxis incH advaxis inc-1O advaxis inc-2":]recently adopted accountin$`recently adopted accountin-1$`drecently adopted accountin-2$grecently adopted accountin-3 Hk3 property and equipment:p4 intangible assetst5 accrued expenses"x6 common stock purchase wa|warrant liability"7 share based compensation#restricted stock units rsus stock optionsdstock options-1!֏net income loss per share#net income loss per share-1",research and development i"general and administrative(item 6 exhibits"section 302 of the sarbane$section 302 of the sarbane-1$&section 302 of the sarbane-2$Hsection 302 of the sarbane-3$section 302 of the sarbane-4$@section 302 of the sarbane-5$µsection 302 of the sarbane-6$section 302 of the sarbane-7"&certificationpursuant to s$certificationpursuant to s-1$certificationpursuant to s-2$certificationpursuant to s-3TZR"!!      !3  @@   l ADVAXIS, INC.January 31, 2019October 31, 2018ASSETSCurrent Assets:Cash and cash equivalentsRestricted cash-Accounts receivableDeferred expenses)Prepaid expenses and other current assetsTotal current assets8Property and equipment (net of accumulated depreciation)3Intangible assets (net of accumulated amortization) Other assets Total assets$LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payableAccrued expensesDeferred revenueCommon stock warrant liabilityOther current liabilitiesTotal current liabilitiesOther liabilitiesTotal liabilities'Commitments and contingencies  Note 10Stockholders equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at January 31, 2019 and October 31, 2018 Liquidation preference of $0 at January 31, 2019 and October 31, 2018Common stock - $0.001 par value; 170,000,000 shares authorized, 69,734,259 and 69,556,452 shares issued and outstanding at January 31, 2019 and October 31, 2018, respectivelyAdditional paid-in capitalAccumulated deficitTotal stockholders equity*Total liabilities and stockholders equityThree Months Ended January 31,20192018RevenueOperating expenses:!Research and development expenses#General and administrative expensesTotal operating expensesIncome (loss) from operationsOther income (expense):Interest income, net3Net changes in fair value of derivative liabilities Other expense1Net income (loss) before benefit for income taxesIncome tax expenseNet income (loss)5Net income (loss) per common share, basic and diluted;Weighted average number of common shares outstanding, basic=Weighted average number of common shares outstanding, dilutedOPERATING ACTIVITIESTAdjustments to reconcile net income (loss) to net cash used in operating activities:Stock compensation$Employee stock purchase plan expense#Gain on change in value of warrants*Loss on disposal of property and equipmentWrite-off of intangible assetsDepreciation expense)Amortization expense of intangible assets*Net amortization of premiums and discounts+Change in operating assets and liabilities:Income tax receivable%Accounts payable and accrued expenses%Net cash used in operating activitiesINVESTING ACTIVITIES-Purchases of short-term investment securities<Proceeds from maturities of short-term investment securities"Purchase of property and equipmentCost of intangible assets3Net cash (used in) provided by investing activitiesFINANCING ACTIVITIES(Net proceeds of issuance of common stock*Proceeds from employee stock purchase planFTax withholdings paid related to net share settlement of equity awards/Employee tax withholdings paid on equity awardsETax shares sold to pay for employee tax withholdings on equity awards)Net cash provided by financing activitiesENet (decrease) increase in cash, cash equivalents and restricted cash?Cash, cash equivalents and restricted cash at beginning of year9Cash, cash equivalents and restricted cash at end of yearThe following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows:\Total cash, cash equivalents and restricted cash shown in condensed statements of cash flows"SUPPLEMENTAL CASH FLOW INFORMATIONCash paid for taxes<SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIESHProperty and equipment included in accounts payable and accrued expenses$-%Recently Adopted Accounting StandardsLImpact of ASC 606 Adoption on Condensed Balance Sheet as of November 1, 2018(in thousands)As reported under ASC 606 Adjustments$Balances without adoption of ASC 606LImpact of ASC 606 Adoption on Condensed Balance Sheet as of January 31, 2019kImpact of ASC 606 Adoption on Condensed Statement of Operations for the Three Months Ended January 31, 2019As reported under ASC 606!Research and Development ExpenseskImpact of ASC 606 Adoption on Condensed Statement of Cash Flows for the Three Months Ended January 31, 20193. PROPERTY AND EQUIPMENTLeasehold improvementsLaboratory equipmentFurniture and fixturesComputer equipmentConstruction in progressTotal property and equipment)Accumulated depreciation and amortizationNet property and equipment4. INTANGIBLE ASSETSPatentsLicensesSoftwareTotal intangiblesAccumulated amortizationIntangible assets5. ACCRUED EXPENSESSalaries and other compensationVendorsProfessional feesTotal accrued expenses76. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITYShares!Weighted Average Exercise Price8Weighted Average Remaining Contractual Life In YearsAggregate Intrinsic Value8Outstanding and exercisable warrants at October 31, 2018 ExercisedExpired8Outstanding and exercisable warrants at January 31, 2019Warrant LiabilityExercise Price Stock Price Expected Term 5.62 years 5.87 years Volatility %95.93%97.47%Risk Free Rate2.43%3.03%7. SHARE BASED COMPENSATIONThree Months Ended January 31,Research and developmentGeneral and administrativeTotalRestricted Stock Units (RSUs)Number of RSUs'Weighted-Average Grant Date Fair Value&Non-vested balance at October 31, 2018Vested Cancelled&Non-vested balance at January 31, 2019 Stock OptionsNumber of Options Weighted-Average Exercise Price Outstanding at October 31, 2018:GrantedCanceled or ExpiredOutstanding at January 31, 2019*Vested and Exercisable at January 31, 20195.50-6.51 years5.50-6.50 yearsExpected Volatility 90.29%-99.32%95.11%-100.34%Expected Dividends0%Risk Free Interest Rate 2.65%-3.15% 2.00%-2.66%NET INCOME (LOSS) PER SHARE Numerator:Net Income (loss)@Earnings attributable to common stockholders  basic and diluted Denominator:KWeighted-average number of common shares used in earnings per share - basic Effect of dilutive stock optionsMWeighted-average number of common shares used in earnings per share - diluted&Earnings per share  basic and dilutedAs of January 31,WarrantsRestricted Stock Units'Research and Development (in thousands)Three Months Ended January 31,Increase (Decrease)$%HPV-associated cancers(78)%*Personalized neoantigen-directed therapies0Hotspot mutation-based  off the shelf therapiesProstate cancerOther expensesPartner reimbursements$Total research & development expense(60MStock-based compensation expense included in research and development expense(75#General and Administrative Expenses Three Months Ended January 31,Increase (Decrease)"General and administrative expense(54OStock-based compensation expense included in general and administrative expense(81Item 6. Exhibits31.1*gCertification of Principal Executive, Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200231.2*fCertification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200232.1*fCertification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 200232.2*-SECTION 302 OF THE SARBANES OXLEY ACT OF 2002eI have reviewed this report on Form 10-Q for the quarter ended January 31, 2019 of Advaxis, Inc.;6Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by thi<s report;#Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;PThe registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)zDesigned such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)sDesigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; andAll significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; andAny fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.By:/s/ Kenneth A. BerlinName:Kenneth A. BerlinTitle:)President and Chief Executive Officer/s/ Molly HendersonMolly Henderson5Executive Vice President, Chief Financial OfficerGCERTIFICATION-PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002zFully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; andoFairly presents, in all material respects, the financial condition and result of operations of the Company. cc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } (,,,,,,, , , , ,,,,,,,,,,,,,,,,      ~ ~   ~ F ~ ~   ~ 3~ b  ~ ~ .  ~ Z~   ~ d~ rh  ~ 6N~ K ~ b~ b ~ ~    ~ 2~ :X ~ b=~ ` ~ n~ E ~ 2@~ e ~ ~  ~ µ~ be  ~  ~ N~  ~ ~ "U !,",#,$,%,&,', ! " " " #~ #~ # $~ $:~ $Z %~ %W~ %^ & ~ &I~ &w '!~ ''~ ''Z ''''PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} =} }  } }  } , @,,,, , , , ,,,,,,,,,,,  " # $   %~ 3~ "  & '~ h~  (~ )~ r[ )~ v~ .a *~ 2~  + ,~ J~ 2 -~ %  .~ ~ v /~ ~  0~ ~  1~ F~ ҿ 2~ K~ ? 3~ ~  4~ .~  b PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } :, @,,,,, , , , , ,,,,,,,,,,,,,,,,,  " # $   5 1~ F~ ҿ 6 7~  ~ + 8~   9~ ^  : ~ n ;~ ~ > <~ v~ & =~ ~ v > ~  ? ~ >~ Z  ~ ~ z @ ~ E  ~  A~ v~  ~ ~  ~ B~  B~ F~ J: C D ~ < E ~ & F~ N~  ,!,#,$,%,&,',(,),+,,,-,/,1,2,3,5,6,8,9, G~ ~ z !H~ !b~ !2 #I $J $~ $) %K~ %:~ %& &L &~ & 'M~ '~ ' (N~ (.~ ( )O~ ):~ )f) +P~ +">~ +% ,Q~ ,~ ,~ -R~ --~ -z- /S 1~ 11~ 161 2 2~ 2F 3T~ 33~ 3z3 5U 6V~ 66~ 66 8W 9X 9Y9~ 99----1111333366669999PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )}  , , @ , , Z [ \ ] ^  _  ~ ~   Y   ~ .~ ~  .3 Z     PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )}   , @ , , ` \ ] ^  _  ~ ~   Y   ~ ~ >~  ( R     PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !}   , , , , a \ b ^  _  %~ 3~ ~~  *"  c~ h~ ~~  Jz R     PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )}   , , , , d \ b ^  _  ~ >~   Y   ~ ~ ~    R     PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  } }  }  ,,,,,,, , , , , e     f~ ~$~ F$ g~ V~ V h~  ~  i~ f~ f j~ F~ F k~ b~  l~ R~  m~ d ~ rh J   PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, , , n     o~ a~ J] p~ & ~ & q~ ~  r~ o~ Bk s~ 2~ Z t~ 6N ~ K J   PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, u     v~ ~  w~ !~ 29 x~ ~  y~ b=~ `J PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 8} }  } } }  } } , @,,,, z { |  }  ~ ~ `~ [~  / Y       ~ `~ [~   YJ  PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,,    ~ [~ [ ~ Q?         :PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,,,,,   # $ ~ ~  ~ ~  ~  ~ +BPH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} &} }  } }  }  , @,,,,,      ~ (\@ ~ .Gz@ ~ ~ w ~ ~ :PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} *} }  } }  }  , @,,,,,    ~ &0.~   ~ ZG~  ~ VE~  ~ %p~  ~  ~ *PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } } } ,,,,,,  # $            PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} M} }  } }  } ,,,,,, , , , , ,   # $    ~ F~ ҿ ~ F~ ҿ  ~ ~  ~ .  ~ .~  ~ K ~ ? R   PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,,,,,  # $ ~ `~  ~ ^~ & ~ ~ L ~ 6M~ ~PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} M} }  } }  }  } } }  } } ,,@ ,,,,, , , , ,,      # $          ~ ~ V~  2    ~ ~ ~   ~  ~ 6 ~ ~  j~  ~  ~ f~ ~ " ~ .~ r~ ^y~   ~ ~ r~ r ~ h ~  ~ c    ~ ~ ~  *          PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} O} } } }  , @ ,,,,      # $          ~ )~ r[~  :    ~ ~ ~          PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d}  ,,,, ,          PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } d}  ,,,, , ~   ~   ~   ~   PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,,         PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,     PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } )} ,,,  !     PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } d}  ,,,, , ~   ~   ~   ~   PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,,         PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,     PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } 5} ,,,  !     PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } d} ,,, ~   ~   PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} ,,, !   PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } d} ,,, ~   ~   PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 5} ,,, !   PH0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@#-I@#-I՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFeWorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8h